Individuals who acquired Johnson & Johnson’s COVID-19 vaccine could have a stronger neutralizing antibody response in the event that they get an mRNA shot because the second dose, Axios reported on Tuesday, citing an individual who has seen knowledge collected by the U.S. Nationwide Institutes of Well being (NIH).
J&J has requested the U.S. Meals and Drug Administration (FDA) to approve a shot of its personal single-dose vaccine because the booster dose. The FDA’s advisers are set to contemplate the necessity on Friday.
The NIH will current the mix-and-match knowledge to the FDA panel on Friday, Axios mentioned.
There have been limitations to the NIH knowledge, in response to the report. Neutralizing antibodies solely stop the virus from getting into cells and replicating, and the report mentioned it was unclear how lengthy the response will final.
The NIH, FDA and J&J didn’t instantly reply to Reuters’ requests for remark.
Two-dose vaccines made by Pfizer Inc and its German companion BioNTech and Moderna Inc use the mRNA expertise.
The well being regulator’s exterior consultants may even focus on the necessity for a further dose of Moderna’s vaccine on Friday.
Scientists on the FDA have mentioned Moderna had not met the entire company’s standards to assist use of booster doses of its COVID-19 vaccine, probably as a result of the efficacy of the shot’s first two doses has remained robust.
(Reporting by Shubham Kalia in Bengaluru; Enhancing by Sriraj Kalluvila)
© 2021 Thomson/Reuters. All rights reserved.